2. Academic Validation
  3. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer

Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer

  • J Med Chem. 2005 Aug 11;48(16):5373-7. doi: 10.1021/jm050242f.
Rainer Albert 1,  Klaus Hinterding,  Volker Brinkmann,  Danilo Guerini,  Constanze Müller-Hartwieg,  Helmut Knecht,  Corinne Simeon,  Markus Streiff,  Trixie Wagner,  Karl Welzenbach,  Frédéric Zécri,  Markus Zollinger,  Nigel Cooke,  Eric Francotte
Affiliations

Affiliation

  • 1 Novartis Institutes for BioMedical Research, Lichtstrasse 35, WSJ-507.3.02, CH-4056 Basel, Switzerland. rainer.albert@novartis.com
PMID: 16078855 DOI: 10.1021/jm050242f
Abstract

In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biologically active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol especially elaborated for phosphates of 1. Starting from the prochiral amino alcohol 1, racemic and enantiomerically pure phosphates of 1 were synthesized. Pure enantiomers were obtained after purification of a partially protected key intermediate on an enantioselective support. The absolute stereochemistry was determined by X-ray diffraction.

Figures